OmniAb

OABI

Market cap $256M

EMERYVILLE, Calif. & DENVER--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners (“ArrowMark”) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors (“Viking”). Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential e.

OmniAb, Inc. ( OABI ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Kurt Gustafson - Executive VP of Finance & CFO Matthew Foehr - President, CEO & Director Conference Call Participants Michael Almisry - Leerink Partners LLC, Research Division Alexander Xenakis Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Brendan Smith - TD Cowen, Research Division Presentation Operator " Kurt Gustafson Executive VP of Finance & CFO " Matthew Foehr President, CEO & Director " Michael Almisry Leerink Partners LLC, Research Division " Leerink Partners LLC, Research Division Unknown Analyst " Alexander Xenakis " Truist Securities | Matthew Hewitt Craig-Hallum Capital Group LLC, Research Division " Craig-Hallum Capital Group LLC, Research Division Brendan Smith TD Cowen, Research Division " TD Cowen, Research Division Unknown Analyst " Operator Good afternoon, and welcome to OmniAb's Third Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2025, and provided operating and partner program updates. “Throughout the third quarter we continued to execute on our strategic initiatives while further demonstrating the value of our proprietary technology platform to a growing base of partners. The number of new program additions so far this year has significantly outpaced last year, bolstering.

OmniAb, Inc. (OABI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three investor conferences during the month of November. 2025 Truist Securities BioPharma Symposium, November 6 at the Lotte New York Palace Hotel. Matt Foehr, Chief Executive Officer, will participate in one-on-one meetings with investors on Thursday, November 6th. Stifel 2025 Healthcare Conference, November 11-13 at the Lotte New York Palace Hotel. Kurt Gustafson, Chief Fi.

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2025, after the close of the U.S. financial markets on Tuesday, November 4, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss third quarter 2025 financial results and business updates       Date:   Tuesday, November 4, 2025       Tim.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace Hotel. Management will be available for one-on-one meetings on Tuesday, September 9th with investors registered for the event. Investors interested in scheduling a meeting with OmniAb management should contact their H.C. Wainwright representative, or email m.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the private placement to be approximately $30 million, before deducting any placement agent fees and offering-related expense.